Catalyst

Slingshot members are tracking this event:

REGENXBIO's (RGNX) Phase 1/2a two year results of RGX-314 in Neovascular Age-related macular degeneration (AMD) to be presented at the American Academy of Ophthalmology 2021 Annual Meeting from November 12-15, 2021

Source Link:
https://www.prnewswire.com/news-releases/regenxbio-announces-rgx-314-data-presentation-at-the-american-academy-of-ophthalmology-2021-annual-meeting-301417322.html

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
RGNX Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Nov 11, 2021
Occurred Source:
http://ir.regenxbio.com/news-releases/news-release-details/regenxbio-presents-additional-positive-interim-data-trials-rgx
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Rgx-314, Neovascular Age-related Macular Degeneration, Amd
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.